is compounded semaglutide banned Did the FDA Ban and Tirzepatide? The U.S. Food and Drug

Promising safety profile: Early trials report tolerability comparable to incretin-based agents, though higher doses are associated with GI side effects (nausea, diarrhea, vomiting, constipation) Clinical Advantage over Others (Clinical Trial Evidence) Phase 2 obesity studies: At 48 weeks, retatrutide delivered weight reductions up to 24%, far exceeding results reported for monotherapy GLP-1 agents

Chen Y, Mezo A, Coskun T, Song M, RoellBokvist WCKB, et al

Clinicians who specialize in diabetes or obesity care are great options if available to you

Patients should report persistent stool changes to their GP, particularly if accompanied by abdominal pain, as GLP-1 therapy carries rare risks of pancreatitis and gallbladder disease